**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A 63-year-old man developed heparin-induced thrombocytopenia (HIT) during treatment with heparin for deep vein thrombosis (DVT) \[*route, dosage and time to reaction onset not stated*\].

The man presented with 1 week history of myalgia, diarrhoea and dry cough. After further investigations, he was diagnosed with COVID-19. For thromboprophylaxis, he started receiving unspecified low-molecular-weight heparins. On day 2 of admission, he was transferred to ICU due to progressive worsening of dyspnoea. On day 7 of admission, he developed a non-occlusive thrombus in the right common femoral vein and was diagnosed with DVT. He received enoxaparin sodium \[enoxaparin\] for the DVT. However his renal function worsened and enoxaparin sodium was changed to heparin \[unfractionated heparin\]. Between day 11 and day 12 of admission, a decrease in platelet count from an initial 30 4000 cells/µL, to 9 6000 cells/µL was observed. His 4T score was 6, which was suggestive of high probability of HIT. His HIT antibody testing (anti-PF4/heparin antibody) by ELISA was positive.

The man\'s heparin drip was switched to argatroban. However, 1 day later, he died after a cardiac arrest. Eventually, his serotonin release assay (SRA) returned positive with 49% of serotonin release at low heparin dose (0.1 IU/mL), which reduced to 0% of serotonin release at high heparin dose (100 IU/mL). The diagnosis of HIT was confirmed.
